BrandWikiReturn

Codexis

Codexis, Inc. is a protein engineering company that develops enzymes for pharmaceutical, food and medical applications.[2][3]

History

Codexis is based in Redwood City, CA and was incorporated in 2002. It went public in April 2010 on NASDAQ,[4] and in October, acquired Maxygen's MolecularBreeding technology portfolio.[5]

Pharmaceutical

Codexis won the Presidential Green Chemistry Challenge Award from the U.S. Environmental Protection Agency (EPA) in 2006 for its work on a building block of Lipitor.[6] It then won a second time in 2010 for its work with Merck & Co. on the active ingredient in Januvia.[7]

Nutrition

In 2017, the company entered a partnership with Tate & Lyle to provide research and development for the production of new ingredients.[8] That same year, Codexis announced a collaboration with Nestle to provide enzymes for metabolic disorders.[9]

Biotherapeutics

In 2017, Codexis developed a recombinant phenylalanine ammonia-lyase (PAL) enzyme, to act as a substitute phenylalanine hydroxylase (PAH) enzyme for people who suffer from phenylketonuria.[3] The enzyme was in-licensed by Nestle Health Sciences.[3]

In 2020, Takeda Pharmaceutical announced a collaboration with Codexis to research and create gene therapies for rare diseases, including lysosomal storage disorders.[10]

Life science

In June 2020, they announced a partnership with Molecular Assemblies to engineer enzymes for DNA synthesis.[11]

Technology

Codexis uses directed evolution to develop its enzymes.[12][13] Using this method, scientists genetically engineer genes, then screen the enzymes produced to see if it creates the properties needed for a specific reaction.[13][7] Their protein engineering platform, called CodeEvolver, uses machine learning and high-throughput experimentation to learn protein sequence changes and their impacts on protein function.[3][14]

External links

References

  1. Codexis Overview retrieved 2011-04-03^
  2. Codexis, Molecular Assemblies Ink Enzyme Engineering Collaboration Agreement GenomeWeb, 23 June 2020, retrieved 2021-03-12^
  3. Embriette Hyde. Engineering the future of biotherapeutics SynBioBeta, 2019-09-04, retrieved 2021-03-12^
  4. Steve Gelsi. Codexis IPO blossoms on Earth Day MarketWatch, retrieved 10 June 2021^
  5. License Agreement - Maxygen, Inc. www.sec.gov^
  6. Codexis, Inc.:News Release^
  7. Greener approach to Januvia cuts costs, ups yield Reuters, 17 June 2010^
  8. foodnavigator.com. Tate & Lyle announce multiyear partnership with Codexis foodnavigator.com, retrieved 2021-05-27^
  9. Rick Mullin. BASF readies a medical food product Chemical & Engineering News, 2017-11-13, retrieved 2021-05-27^
  10. Codexis and Takeda partner on gene therapies for rare diseases www.pharmaceutical-technology.com, retrieved 2021-06-18^
  11. Codexis, Molecular Assemblies Ink Enzyme Engineering Collaboration Agreement Genomeweb, 2020-06-23, retrieved 24 June 2021^
  12. Jerry Jeff says. Xconomy: Codexis Morphs From Big Science Project Into $100M Business Xconomy, 2010-10-27, retrieved 2021-05-24^
  13. Jerry Jeff says. Xconomy: Codexis Morphs From Big Science Project Into $100M Business Xconomy, 2010-10-27, retrieved 2021-06-02^
  14. Patenting Considerations for Artificial Intelligence in Biotech and Synthetic Biology JD Supra^